CFO Farag Kameel D. Buys 1,728 ADSs—Akari Therapeautics’ Insider Buying Sparks Optimism Amid 78% Year‑to‑Date Decline
Akari Therapeutics CFO’s fresh $7.52 ADS purchase fuels optimism—insider buying suggests the stock may be undervalued amid a volatile pharma landscape.
3 minutes to read